0000000000213459

AUTHOR

Sebastian Grosicki

showing 3 related works from this author

Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group

2020

Background Although the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients. Aims In this study we investigated risk factors associated with EM in MM patients initially treated with novel-agent containing regimen. Methods We conducted a multicenter (15 Polish sites) retrospective study a cohort of symptomatic MM pts diagnosed between October 2006 and November 2019 and living < 365 days (d) after diagnosis. All pts were dead at the time of the analysis. …

medicine.medical_specialtybusiness.operationbusiness.industryImmunologyRetrospective cohort studyCell BiologyHematologymedicine.diseaseOctapharmaBiochemistryThalidomideRegimenNovel agentsInternal medicineCohortMedicineIn patientbusinessMultiple myelomamedicine.drugBlood
researchProduct

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

2018

© 2018 The Authors.

MaleCancer ResearchBoronic Acid[SDV]Life Sciences [q-bio]bortezomib ; global ; observational study ; routine practice ; stem cell transplantationSalvage therapyPractice PatternsDexamethasoneBortezomibRoutine practice0302 clinical medicineBortezomib; Global; Observational study; Routine practice; Stem cell transplantationhemic and lymphatic diseasesObservational studyAntineoplastic Combined Chemotherapy Protocols80 and overProspective StudiesPractice Patterns Physicians'Prospective cohort studyLenalidomideComputingMilieux_MISCELLANEOUSMultiple myelomaAged 80 and overBortezomibStem cell transplantationGlobalHematologyMiddle AgedBoronic Acids3. Good healthThalidomideSurvival RateTreatment OutcomeLocalOncology030220 oncology & carcinogenesisBortezomib; Global; Observational study; Routine practice; Stem cell transplantation; Hematology; Oncology; Cancer ResearchFemaleMultiple MyelomaBortezomib; Global; Observational study; Routine practice; Stem cell transplantation; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence Local; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome; Practice Patterns Physicians'; Salvage Therapymedicine.drugHumanAdultmedicine.medical_specialty/NOFollow-Up Studie03 medical and health sciencesInternal medicinemedicineHumansSurvival rateLenalidomideAgedSalvage TherapyPhysicians'Antineoplastic Combined Chemotherapy Protocolbusiness.industrySettore MED/15medicine.diseaseTransplantationThalidomideSettore MED/15 - MALATTIE DEL SANGUEProspective StudieNeoplasm RecurrenceNeoplasm Recurrence Localbusiness030215 immunologyFollow-Up StudiesClinical lymphoma, myelomaleukemia
researchProduct

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical tr…

2019

BACKGROUND: The adjuvanted recombinant zoster vaccine (Shingrix) can prevent herpes zoster in older adults and autologous haemopoietic stem cell transplant recipients. We evaluated the safety and immunogenicity of this vaccine in adults with haematological malignancies receiving immunosuppressive cancer treatments. METHODS: In this phase 3, randomised, observer-blind, placebo-controlled study, done at 77 centres worldwide, we randomly assigned (1:1) patients with haematological malignancies aged 18 years and older to receive two doses of the adjuvanted recombinant zoster vaccine or placebo 1-2 months apart during or after immunosuppressive cancer treatments, and stratified participants acco…

AdultMaleHerpesvirus 3 Humanmedicine.medical_specialtyAdolescentPopulationAntineoplastic AgentsAntibodies ViralPlaceboHematological malignanciesImmunocompromised HostYoung Adult03 medical and health sciences0302 clinical medicineViral Envelope ProteinsInternal medicinemedicineHerpes Zoster VaccineHumansSingle-Blind Method030212 general & internal medicineeducationAdverse effectFatigueImmunity CellularVaccines Syntheticeducation.field_of_studyVaccinesReactogenicityH. Zosterbusiness.industryImmunogenicityMiddle AgedCD4 Lymphocyte CountInjection Site ReactionVaccinationClinical trialInfectious DiseasesHematologic Neoplasms030220 oncology & carcinogenesisH. Zoster; Vaccines; Hematological malignanciesFemaleZoster vaccinebusinessVaccinemedicine.drug
researchProduct